LGVN (Longeveron Inc.) Stock Financials & Earnings | Market Cap Arena

LGVN (Longeveron Inc.) Stock Financials & Earnings | Market Cap Arena

LGVNLongeveron Inc.

Mkt Cap$20M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$1M

Net Income (TTM)-$21M

EPS (TTM)-$1.33

Free Cash Flow (TTM)-$17M

Gross Margin74.9%

Op. Margin-1542.7%

Net Margin-1485.1%

FCF Margin-1181.6%

P/S Ratio (TTM)13.7x

P/E Ratio (TTM)—

YoY Rev Growth-22.4%

Employees—

Earnings Reports

Next: Q4 2025 · Mar 13

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$121K	-$55K	-$5M
Q1 23	$238K	$35K	-$5M
Q2 23	$217K	$93K	-$6M
Q3 23	$150K	$54K	-$5M
Q4 23	$63K	-$2K	-$5M
Q1 24	$548K	$329K	-$4M
Q2 24	$468K	$344K	-$4M
Q3 24	$773K	$682K	-$5M
Q4 24	$603K	$530K	-$4M
Q1 25	$381K	$275K	-$5M
Q2 25	$316K	$146K	-$5M
Q3 25	$137K	$125K	-$7M

Valuation

Quarter	P/S	P/E
Q4 22	16.1x	—
Q1 23	18.0x	—
Q2 23	23.3x	—
Q3 23	27.0x	—
Q4 23	29.4x	—
Q1 24	20.1x	—
Q2 24	16.0x	—
Q3 24	10.6x	—
Q4 24	8.2x	—
Q1 25	8.8x	—
Q2 25	9.5x	—
Q3 25	13.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$2M	-$2M
Q1 23	-$6M	-$6M
Q2 23	-$5M	-$5M
Q3 23	-$5M	-$5M
Q4 23	-$4M	-$4M
Q1 24	-$3M	-$3M
Q2 24	-$5M	-$5M
Q3 24	-$3M	-$3M
Q4 24	-$3M	-$3M
Q1 25	-$5M	-$5M
Q2 25	-$4M	-$4M
Q3 25	-$5M	-$5M

Capital Expenditures

CapEx

Quarter	CapEx
Q4 22	$66K
Q1 23	$42K
Q2 23	$92K
Q3 23	$115K
Q4 23	$259K
Q1 24	$47K
Q2 24	$196K
Q3 24	$430K
Q4 24	$13K
Q1 25	$27K
Q2 25	$161K
Q3 25	$57K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	-42.1%	+26.4%
Q1 23	-35.7%	+31.6%
Q2 23	-53.4%	+26.5%
Q3 23	-43.4%	-2.6%
Q4 23	-47.9%	+2.6%
Q1 24	+130.3%	-6.4%
Q2 24	+115.7%	-33.1%
Q3 24	+415.3%	+2.1%
Q4 24	+857.1%	-11.2%
Q1 25	-30.5%	+19.9%
Q2 25	-32.5%	+44.0%
Q3 25	-82.3%	+37.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$306K	252.9%
Q1 23	$421K	176.9%
Q2 23	$700K	322.6%
Q3 23	$499K	332.7%
Q4 23	$413K	655.6%
Q1 24	$295K	53.8%
Q2 24	$200K	42.7%
Q3 24	$1M	181.1%
Q4 24	$2M	386.1%
Q1 25	$340K	89.2%
Q2 25	$513K	162.3%
Q3 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q4 22	$3M	$2M	$285K
Q1 23	$3M	$2M	—
Q2 23	$2M	$4M	—
Q3 23	$2M	$3M	$280K
Q4 23	$2M	$3M	$203K
Q1 24	$2M	$2M	—
Q2 24	$2M	$2M	—
Q3 24	$2M	$3M	—
Q4 24	$2M	$3M	—
Q1 25	$3M	$3M	—
Q2 25	$3M	$3M	—
Q3 25	$4M	$4M	—

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$11M	$9M	$20M
Q1 23	$5M	$9M	$14M
Q2 23	$3M	$6M	$9M
Q3 23	$2M	$2M	$4M
Q4 23	$5M	$412K	$5M
Q1 24	$2M	$351K	$2M
Q2 24	$12M	$0	$12M
Q3 24	$23M	$0	$23M
Q4 24	$19M	$0	$19M
Q1 25	$14M	$0	$14M
Q2 25	$10M	$0	$10M
Q3 25	$9M	$0	$9M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	2M	+0.1%
Q1 23	2M	+0.1%
Q2 23	2M	+0.3%
Q3 23	2M	+0.3%
Q4 23	0	-100.0%
Q1 24	3M	—
Q2 24	7M	+159.0%
Q3 24	14M	+109.3%
Q4 24	15M	+9.3%
Q1 25	15M	+0.4%
Q2 25	15M	+0.4%
Q3 25	18M	+22.4%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 18	—	—
FY 19	—	—
FY 20	$469K	12
FY 21	$73K	18
FY 22	$64K	19
FY 23	$31K	23
FY 24	$96K	25